No profile data available.
Regenxbio Inc. (RGNX) is a healthcare company in the brain and nerve treatment drugs industry, based in Rockville, United States, with about 371 full-time employees.
It reported revenue of $170.44 million for fiscal year 2025, up 104.5% from fiscal year 2024, and net income of -$193.88 million. Japan was its largest region in fiscal year 2025, with 44% of revenue. Its market capitalization was $532.73 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Regenxbio reported $170.44 million in revenue for fiscal year 2025, up 104.5% from $83.33 million in fiscal year 2024.
Japan: 44% of revenue by region in fiscal year 2025, followed by Foreign (31%).
$532.73 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Solid Biosciences Inc. (SLDB), Design Therapeutics, Inc. (DSGN), Bright Minds Biosciences Inc. (DRUG), Neurogene Inc. (NGNE).